Phytochemical and Docking Evaluation of Phyllanthus Niruri L. Extract Reveals Cytotoxic Potential Against Cervical and Breast Cancer Cells

Phyllanthus niruri L., a widely used traditional medicinal plant, has been reported to possess various therapeutic properties, including anticancer potential. However, its direct cytotoxic effects on specific cancer cell lines such as HeLa (cervical cancer) and MDA-MB-231 (triple-negative breast cancer) remain underexplored. This study aimed to evaluate the anticancer efficacy of the aqueous leaf extract of Phyllanthus niruri against these cell lines using in vitro and in silico approaches. The MTT assay revealed that the extract induced significant dose-dependent cytotoxicity in both cell lines, with an IC₅₀ of 0.1924 µg/mL for HeLa and 0.017 µg/mL for MDA-MB-231, indicating a stronger effect on breast cancer cells even at lower concentrations. To further support the anticancer potential, antioxidant activity was assessed via DPPH free radical scavenging assay, which showed increased scavenging capacity with rising concentrations, suggesting the presence of bioactive phytochemicals. GC-MS analysis identified key phytoconstituents, including alkanes, alkenes, phenolic compounds, alcohols, thiadiazoles, and terpenes. Molecular docking studies were performed using the breast cancer target protein 6NM8, where most compounds exhibited weak to moderate binding affinities. Among these, 2-Hexyl-1-decanol showed the most promising interaction (-5.1 kcal/mol) with acceptable ADME properties. These findings highlight the cytotoxic efficacy of Phyllanthus niruri L., especially against MDA-MB-231 cells, and suggest its potential as a lead source for anticancer therapeutics. Further studies are warranted to isolate individual active compounds and elucidate their mechanisms of action.

Anticancer, HeLa, MDAMB231, Phyllanthus niruri

1. K. Narendra, J. Swathi, K. M. Sowjanya, and A. K. Satya, “Phyllanthus niruri : A Review on its Ethno Botanical, Phytochemical and Pharmacological Profile,” J. Pharm. Res., vol. 5, no. 9, pp. 4681–4691, 2012. [Google Scholar] [Crossref]

2. O. E. Abdel-Sattar et al., “Hypophyllanthin and Phyllanthin from Phyllanthus niruri Synergize Doxorubicin Anticancer Properties against Resistant Breast Cancer Cells,” ACS Omega, vol. 8, no. 31, pp. 28563–28576, 2023, doi: 10.1021/acsomega.3c02953. [Google Scholar] [Crossref]

3. I. M. D. M. Adnyana et al., “Activity and potential of Phyllantus niruri L. and Phyllantus urinaria L. as Hepatitis B virus inhibitors: A narrative review of the SANRA protocol,” J. Res. Pharm., vol. 28, no. 1, pp. 335–350, 2024, doi: 10.29228/jrp.700. [Google Scholar] [Crossref]

4. B. A. Oyekanmi, I. B. Osho, and J. C. Kolawole, “Antimicrobial, phytochemical and pharmacological properties of Phyllanthus niruri linn,” Res. J. Heal. Sci., vol. 11, no. 2, pp. 108–118, 2023, doi: 10.4314/rejhs.v11i2.4. [Google Scholar] [Crossref]

5. I. Rosidah et al., “Acute and Subchronic Toxicological Study of the Cocktail Extract from Curcuma xanthorrhiza Roxb, Phyllanthus niruri L. and Morinda citrifolia L.,” J. Toxicol., vol. 2024, 2024, doi: 10.1155/2024/9445226. [Google Scholar] [Crossref]

6. M. S. Hossain, H. K. Shaha, S. J. Shipa, M. S. Islam, F. Ahmed, and N. Saqueeb, “evaluation of whole plant extract of Phyllanthus niruri L .,” vol. 59, no. 4, pp. 195–204, 2024. [Google Scholar] [Crossref]

7. S. P. Sakti et al., “The effect of Phyllanthus niruri and Catharanthus roseus on Macrophage Polarization in Breast Cancer Mice Model,” J. Trop. Life Sci., vol. 14, no. 1, pp. 21–26, 2024, doi: 10.11594/jtls.14.01.03. [Google Scholar] [Crossref]

8. S. P. Panjala et al., “Anti-cancer activity of crude Slrp protein conjugated mesoporous silica nanoparticles in HeLa Cell Lines: An in vitro approach,” J. Appl. Nat. Sci., vol. 16, no. 1, pp. 364–377, 2024, doi: 10.31018/jans.v16i1.5285. [Google Scholar] [Crossref]

9. N. Ibarra, “HeLa Cells, Cer ical Cancer, and the HPV Vaccine,” vol. VI, no. September, pp. 1–13, 2023, [Online]. Available: https://teachers.yale.edu/pdfs/curriculum_pdfs/17.06.06.pdf [Google Scholar] [Crossref]

10. ling liao, “Inequality in Breast Cancer: Global Statistics from 2022 to 2050,” The Breast, vol. 79, no. November 2024, p. 103851, 2024, doi: 10.1016/j.breast.2024.103851. [Google Scholar] [Crossref]

11. S. El-Sahli et al., “Nanoparticle-Mediated mRNA Delivery to Triple-Negative Breast Cancer (TNBC) Patient-Derived Xenograft (PDX) Tumors,” ACS Pharmacol. Transl. Sci., pp. 0–9, 2025, doi: 10.1021/acsptsci.4c00597. [Google Scholar] [Crossref]

12. I. Soerjomataram and F. Bray, “Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070,” Nat. Rev. Clin. Oncol., vol. 18, no. 10, pp. 663–672, 2021, doi: 10.1038/s41571-021-00514-z. [Google Scholar] [Crossref]

13. N. H. Y. Li and C. I. Li, “Incidence Rate Trends of Breast Cancer Overall and by Molecular Subtype by Race and Ethnicity and Age.,” JAMA Netw. open, vol. 8, no. 1, p. e2456142, 2025, doi: 10.1001/jamanetworkopen.2024.56142. [Google Scholar] [Crossref]

• Green Synthesis of Zinc Nanoparticles Using Phaseolus vulgaris Extract: Evaluation of Antimicrobial, Anticancer, and in Silico Properties